Solara Active Pharma Sciences: No Deviation in Rights Issue Proceeds Utilization

Solara Active Pharma Sciences Ltd has submitted its Monitoring Agency Report for the quarter ended June 30, 2026, issued by CRISIL Ratings Limited. The report confirms that there has been no deviation or variation in the utilization of proceeds from its Rights Issue compared to the objects stated in the Letter of Offer. The Rights Issue, which involved equity shares, had a total issue size of ₹449.95 crore, with net proceeds of ₹446.95 crore being monitored by CRISIL. The company has declared that the utilization of funds aligns with the stated objectives, providing assurance to investors regarding the proper deployment of capital raised.